| Literature DB >> 31665100 |
Timothy J J Inglis1,2,3, Teagan F Paton2, Malgorzata K Kopczyk2, Kieran T Mulroney1,4,3, Christine F Carson3.
Abstract
Purpose. Antimicrobial susceptibility is slow to determine, taking several days to fully impact treatment. This proof-of-concept study assessed the feasibility of using machine-learning techniques for analysis of data produced by the flow cytometer-assisted antimicrobial susceptibility test (FAST) method we developed.Methods. We used machine learning to assess the effect of antimicrobial agents on bacteria, comparing FAST results with broth microdilution (BMD) antimicrobial susceptibility tests (ASTs). We used Escherichia coli (1), Klebsiella pneumoniae (1) and Staphylococcus aureus (2) strains to develop the machine-learning algorithm, an expanded panel including these plus E. coli (2), K. pneumoniae (3), Proteus mirabilis (1), Pseudomonas aeruginosa (1), S. aureus (2) and Enterococcus faecalis (1), tested against FAST and BMD (Sensititre, Oxoid), then two representative isolates directly from blood cultures.Results. Our data machines defined an antibiotic-unexposed population (AUP) of bacteria, classified the FAST result by antimicrobial concentration range, and determined a concentration-dependent antimicrobial effect (CDE) to establish a predicted inhibitory concentration (PIC). Reference strains of E. coli, K. pneumoniae and S. aureus tested with different antimicrobial agents demonstrated concordance between BMD results and machine-learning analysis (CA, categoric agreement of 91 %; EA, essential agreement of 100 %). CA was achieved in 35 (83 %) and EA in 28 (67 %) by machine learning on first pass in a challenge panel of 27 Gram-negative and 15 Gram-positive ASTs. Same-day AST results were obtained from clinical E. coli (1) and S. aureus (1) isolates.Conclusions. The combination of machine learning with the FAST method generated same-day AST results and has the potential to aid early antimicrobial treatment decisions, stewardship and detection of resistance.Entities:
Keywords: Escherichia coli; Klebsiella pneumoniae; Staphylococcus aureus; antimicrobial susceptibility test; flow cytometer; machine learning
Mesh:
Substances:
Year: 2019 PMID: 31665100 PMCID: PMC7451041 DOI: 10.1099/jmm.0.001092
Source DB: PubMed Journal: J Med Microbiol ISSN: 0022-2615 Impact factor: 2.472
Fig. 1.Analysis of antimicrobial susceptibility flow cytometer data by supervised machine learning relies on a standardised data handling workflow, comprising conversion of flow cytometer data into .CSV format, assembly of an orderly collection of cleaned data files, which are then linked (concatenated), analytical parameters selected, classified into a hierarchy to optimse information gain, and then displayed to present antimicrobial concentration-dependent effects that can be calibrated against a Minimum Inhibitory Concentration.
Fig. 2.Antimicrobial-unexposed population. Antimicrobial unexposed bacteria (blue) and background particulate noise (red), showing (left) and (right) . Differences in unexposed bacterial density are due to balancing the numbers of unstained unexposed (blue) and background noise (control, red) events to avoid classification bias.
Fig. 5.Data machine 3. Data mining workflow used to assemble flow cytometer data files from ATCC 700603 to determine Gentamicin PIC, showing data structure, sampling, selection, classification and visualisation (Orange v3.20.1).
Fig. 3.Visualising antimicrobial susceptibility: Gentamicin-exposed E. coli. Top panel: Data Machine 2 (a) Principal Component Analysis, Scree diagram showing dimensionality of data, (b) tree classification with reference to the AUP (Blue). right) tree classification with reference to the AUP (Blue). Middle panel: (c) scatter map and (d) polynomial classification both with toggle on/off for specific concentrations to enable detection of concentration-dependent effect. Bottom panel, falling bacterial population density in AUP zone. (e) Data Machine 2. Density histogram of antimicrobial-unexposed population (AUP, blue), and lowest (red) and highest (green) Gentamicin-concentration-exposed ATCC 25922. The loss of events between low and high Gentamicin concentration indicates a likely concentration-dependent effect within the tested range of concentrations. (f) Data Machine 3. The corresponding frequency distribution histogram featuring all tested concentrations and shows progressive loss of event density in the AUP zone. Predicted inhibitory concentration (PIC) = 2 µg ml−1.
Data-machine development and calibration series, antimicrobial susceptibility test results
|
Species, strain |
Antimicrobial agent |
BMDa |
FAST |
BPd |
S-Re |
corrnf | |
|---|---|---|---|---|---|---|---|
|
psb |
smlc | ||||||
|
|
Amikacin |
2 |
1 |
2 |
8 |
S | |
|
ATCC 25922 |
Aztreonam |
1 |
1 |
1 |
1 |
S | |
|
Ciprofloxacin |
≤0.12 |
≤0.12 |
≤0.12 |
0.25 |
S | ||
|
Colistin |
1 |
≤0.25 |
≤0.25 |
2 |
S | ||
|
Cefepime |
≤1 |
≤1 |
≤1 |
1 |
S | ||
|
Gentamicin |
2 |
0.5 |
0.5 |
2 |
S |
2/S | |
|
Imipenem |
≤0.25 |
≤0.25 |
≤0.25 |
2 |
S | ||
|
Levofloxacin |
≤0.12 |
≤0.12 |
≤0.12 |
0.5 |
S | ||
|
Meropenem |
≤0.12 |
≤0.12 |
≤0.25 |
2 |
S | ||
|
Piperacillin/tazobactam |
4 |
4 |
2 |
8 |
S | ||
|
Co-trimoxazole |
≤0.12 |
≤0.12 |
0.25 |
2 |
S | ||
|
Ceftazidime |
≤0.5 |
≤0.5 |
≤0.5 |
1 |
S | ||
|
Tobramycin |
2 |
0.5 |
≤0.25 |
2 |
S |
1/S | |
|
|
Amikacin |
1 |
1 |
1 |
8 |
S | |
|
ATCC 700603 |
Aztreonam |
>64 |
32 |
>64 |
1 |
R | |
|
Ciprofloxacin |
1 |
0.5 |
0.5 |
0.25 |
R | ||
|
Colistin |
1 |
≤0.25 |
≤0.25 |
2 |
S | ||
|
Cefepime |
8 |
≤1 |
32 |
1 |
R | ||
|
Gentamicin |
8 |
4 |
4 |
2 |
R | ||
|
Imipenem |
0.5 |
0.5 |
2 |
2 |
S | ||
|
Levofloxacin |
2 |
0.5 |
2 |
0.5 |
S | ||
|
Meropenem |
≤0.12 |
≤0.12 |
≤0.12 |
2 |
S | ||
|
Piperacillin/tazobactam |
32 |
8 |
>64 |
8 |
R | ||
|
Co-trimoxazole |
2 |
2 |
4 |
2 |
I | ||
|
Ceftazidime |
>32 |
32 |
>32 |
1 |
R | ||
|
Tobramycin |
8 |
2 |
4 |
2 |
R | ||
|
|
Amikacin |
2 |
2 |
2 |
16 |
S | |
|
ATCC 25923 |
Azithromycin |
1 |
≤0.5 |
1 |
2 |
S | |
|
Ciprofloxacin |
0.5 |
0.25 |
0.25 |
1 |
S | ||
|
Clarithromycin |
0.25 |
0.25 |
0.25 |
2 |
S | ||
|
Clindamycin |
≤0.12 |
≤0.12 |
0.25 |
0.5 |
S | ||
|
Cefoxitin |
4 |
2 |
2 |
4 |
S | ||
|
Gentamicin |
0.5 |
0.25 |
0.5 |
1 |
S | ||
|
Levofloxacin |
0.25 |
≤0.12 |
≤0.12 |
1 |
S | ||
|
Linezolid |
1 |
1 |
1 |
4 |
S | ||
|
Moxifloxacin |
≤0.06 |
≤0.06 |
≤0.06 |
0.25 |
S | ||
|
Norfloxacin |
≤1 |
≤1 |
≤1 |
| |||
|
Ofloxacin |
0.5 |
0.25 |
0.25 |
1 |
S | ||
|
Penicillin |
≤0.03 |
≤0.03 |
≤0.03 |
0.125 |
S | ||
|
Teicoplanin |
0.5 |
≤0.25 |
0.5 |
2 |
S | ||
|
Tobramycin |
0.25 |
0.5 |
0.25 |
1 |
S | ||
|
Vancomycin |
2 |
1 |
1 |
2 |
S | ||
|
|
Amikacin |
4 |
2 |
4 |
16 |
S | |
|
ATCC 29213 |
Azithromycin |
2 |
1 |
1 |
2 |
S | |
|
Ciprofloxacin |
0.5 |
≤0.12 |
≤0.12 |
1 |
S | ||
|
Clarithromycin |
0.5 |
≤0.25 |
≤0.25 |
2 |
S | ||
|
Clindamycin |
≤0.12 |
≤0.12 |
≤0.12 |
0.5 |
S | ||
|
Cefoxitin |
4 |
4 |
4 |
4 |
S | ||
|
Gentamicin |
1 |
0.25 |
0.25 |
1 | |||
|
Levofloxacin |
0.25 |
≤0.12 |
0.25 |
1 |
S | ||
|
Linezolid |
4 |
2 |
2 |
4 |
R | ||
|
Moxifloxacin |
≤0.06 |
≤0.06 |
≤0.06 |
0.25 |
S | ||
|
Norfloxacin |
2 |
≤1 |
≤1 |
| |||
|
Ofloxacin |
≤0.25 |
≤0.25 |
≤0.25 |
1 |
S | ||
|
Penicillin |
>0.5 |
0.25 |
0.5 |
0.12 |
R | ||
|
Teicoplanin |
1 |
≤0.25 |
0.5 |
2 |
S | ||
|
Tobramycin |
1 |
0.5 |
0.25 |
1 |
S | ||
|
Vancomycin |
≤1 |
≤1 |
≤1 |
2 |
S | ||
a, BMD, broth microdilution.
b, ps, proprietary software.
c, sml, supervised machine learning.
d, BP, EUCAST susceptible breakpoint (μg ml−1).
e, S-R, sensitive/resistant categorization.
f, corrn, corrected by re-training pipeline.
Expanded bacterial challenge set, single-pass antimicrobial susceptibility test results
|
Species |
Strain |
Antimicrobial |
PIC(cat.) |
MIC(cat.) |
CA |
EA |
|---|---|---|---|---|---|---|
|
|
ATCC 1705 |
Meropenem |
4 (I) |
8 (I) |
Y |
Y |
|
|
ATCC 1706 |
Meropenem |
≤0.12 (S) |
2 (S) |
Y |
N |
|
|
ATCC 13883 |
Meropenem |
≤0.12 |
≤0.12 |
Y |
Y |
|
|
ATCC 700603 |
Meropenem |
≤0.12 (S) |
≤1 (S) |
Y |
N |
|
|
ATCC 25922 |
Meropenem |
≤0.12 (S) |
≤0.12 (S) |
Y |
Y |
|
|
ATCC 35218 |
Meropenem |
0.5 (S) |
0.12 (S) |
Y |
N |
|
|
−2841 |
Meropenem |
≤0.12 (S) |
≤0.12 (S) |
Y |
Y |
|
|
−9545 |
Meropenem |
≤0.12 (S) |
≤0.12 (S) |
Y |
Y |
|
|
ATCC 27853 |
Meropenem |
≤0.12 (S) |
0.5 (S) |
Y |
N |
|
|
ATCC 1705 |
Ceftazidime |
4 (I) |
8 (I) |
Y |
Y |
|
|
ATCC 1706 |
Ceftazidime |
≤0.5 (S) |
32 (R) |
N |
N |
|
|
ATCC 13883 |
Ceftazidime |
≤0.5 (S) |
≤0.5 (S) |
Y |
Y |
|
|
ATCC 700603 |
Ceftazidime |
8 (R) |
32 (R) |
Y |
N |
|
|
ATCC 25922 |
Ceftazidime |
≤0.5 (S) |
≤0.5 (S) |
Y |
Y |
|
|
ATCC 35218 |
Ceftazidime |
16 (R) |
≤0.5 (S) |
N |
N |
|
|
−2841 |
Ceftazidime |
0.5 (S) |
0.5 (S) |
Y |
Y |
|
|
−9545 |
Ceftazidime |
≤0.5 (S) |
≤0.5 (S) |
Y |
Y |
|
|
ATCC 27853 |
Ceftazidime |
1 (S) |
4 (I) |
N |
N |
|
|
ATCC 1705 |
Gentamicin |
0.5 (S) |
≤2 (S) |
Y |
N |
|
|
ATCC 1706 |
Gentamicin |
0.25 (S) |
1 (S) |
Y |
N |
|
|
ATCC 13883 |
Gentamicin |
1 (S) |
0.5 (S) |
Y |
Y |
|
|
ATCC 700603 |
Gentamicin |
4 (I) |
8 (I) |
Y |
Y |
|
|
ATCC 25922 |
Gentamicin |
1 (S) |
2 (S) |
Y |
Y |
|
|
ATCC 35218 |
Gentamicin |
16 |
1 |
N |
N |
|
|
−2841 |
Gentamicin |
0.5 (S) |
0.5 (S) |
Y |
Y |
|
|
−9545 |
Gentamicin |
2 (S) |
4 (S) |
Y |
Y |
|
|
ATCC 27853 |
Gentamicin |
≤0.25 (S) |
0.5 (S) |
Y |
Y |
|
Gram negative |
23/27 (85 %) |
16/27 (59 %) | ||||
|
|
ATCC 25923 |
Penicillin |
≤0.03(S) |
≤0.03(S) |
Y |
Y |
|
|
ATCC 29213 |
Penicillin |
0.12 (S) |
>0.5(R) |
N |
N |
|
|
ATCC 33592 |
Penicillin |
≥0.5 (R) |
>0.5 |
Y |
Y |
|
|
−6885 |
Penicillin |
≥0.5 (R) |
>0.5 |
Y |
Y |
|
|
ATCC 29212 |
Penicillin |
≥0.5 (R) |
>0.5 |
Y |
Y |
|
|
ATCC 25923 |
Cefoxitin |
≤1 |
1 |
Y |
Y |
|
|
ATCC 29213 |
Cefoxitin |
2 |
4 |
Y |
Y |
|
|
ATCC 33592 |
Cefoxitin |
2 |
16(R) |
N |
N |
|
|
−6885 |
Cefoxitin |
16 (R) |
>16 |
Y |
Y |
|
|
ATCC 29212 |
Cefoxitin |
≥16 (R) |
>16 |
Y |
Y |
|
|
ATCC 25923 |
Vancomycin |
≤0.5(S) |
2(S) |
Y |
Y |
|
|
ATCC 29213 |
Vancomycin |
1 (S) |
1(S) |
Y |
Y |
|
|
ATCC 33592 |
Vancomycin |
1 (S) |
2(S) |
Y |
Y |
|
|
−6885 |
Vancomycin |
1 (S) |
4(R) |
N |
N |
|
|
ATCC 29212 |
Vancomycin |
2(S) |
4(S) |
Y |
Y |
|
Gram positive |
12/15 (80 %) |
12/15 (80 %) | ||||
|
|
35/42 (83 %) |
28/42 (67 %) |
a, PIC (cat.); predicted inhibitory concentration (categoric result [S,I,R]).
b, MIC (cat.); broth MIC (cat.); broth microdilution MIC (categoric result [S,I,R]).
c, CA; categoric agreement [yes/no].
d, EA; essential agreement [yes/no].
Clinical isolates, single-pass antimicrobial susceptibility test results
|
Species, isolate |
Antimicrobial agent |
BMD |
FAST |
BP |
S-R |
corrn | |
|---|---|---|---|---|---|---|---|
|
ps |
sml | ||||||
|
|
Piperacillin/tazobactam |
4 |
2 |
>64 |
8 |
R |
4/S |
|
1A |
Gentamicin |
0.5 |
0.5 |
0.5 |
2 |
S | |
|
Meropenem |
≤0.12 |
≤0.12 |
≤0.12 |
2 |
S | ||
|
|
Penicillin |
>0.5 |
>0.5 |
>0.5 |
0.12 |
R | |
|
5B |
Cefoxitin |
>16 |
16 |
16 |
4 |
R | |
|
Vancomycin |
1 |
0.5 |
1 |
2 |
S | ||
a, BMD, broth microdilution.
b, ps, proprietary software.
c, sml, supervised machine learning.
d, BP, EUCAST susceptible breakpoint (μg ml−1).
e, S-R, sensitive/resistant categorization.
f, corrn, corrected by re-training pipeline.
Machine-learning terms used
|
Phrase |
Explanation |
|---|---|
|
Machine learning |
The use of computers to automate learning from input data |
|
Supervised (SML) |
Use of computers to analyse large data sets, starting with a set of labelled examples (training set) to predict specific outcomes |
|
Unsupervised (UML) |
Fully automated machine learning that does not require the expertise of a user to supervise training |
|
Data mining |
The examination of large data sets to generate new information |
|
Classification |
The prediction of class labels or categories using a series of learning steps |
|
Tree classification |
A commonly used form of predictive modelling in which recursive binary partitioning is applied to categoric variables. |
|
Visualization |
The presentation of data in picture form to assist decision-making |
|
Concatenation |
Connection of a series of discrete sets of similarly formatted data to preserve their source as a feature |
|
Jitter |
Displacement of data points to assist their individual visibility by reducing two-dimensional overlap |
|
Principal component analysis (PCA) |
The transformation of potential correlates into sets of non-correlating data known as principal components in which the first component has greatest variance. |